Aim: To measure time saving associated with the subcutaneous (SC) fixed-dose combination of pertuzumab and trastuzumab (PH FDC SC) compared with intravenous (IV) pertuzumab and trastuzumab in patients with HER2-positive breast cancer. Materials PH FDC SC was administered in 50% of the visits resulted in a total of 150 occurrences of treatment administration. The mean age was 47.0 ± 10.9 years. Patients' length of stay was significantly shorter in the SC arm by a mean difference of 190.9 ± 13.6 min saved per patient (95% CI: 163.9, 217.9). Median pharmacist preparation time was significantly shorter (8 min Q1: 4; Q3: 15; p = 0.006) with the SC formulation compared with the IV formulation (13 min Q1: 6; Q3: 28). When extrapolated, switching to the SC formulation would save 2468.25 clinical hours saved annually across nursing and pharmacy services. Conclusion: PH FDC SC was associated with significant time savings for both patients and healthcare providers. The transition to SC administration unlocked 2468.25 clinical hours annually, translating into notable indirect cost reductions through optimized resource utilization and improved operational efficiency compared with IV administration.
Khaled H.A. Al Qawasmeh (Mon,) studied this question.